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ABSTRACT 
Approximately one-third of the human population is infected with MTB, the 
causative agent of TB. The emergence of drug- and multidrug-resistant TB is caused 
by mycobacterial strains that exhibit antibiotic resistance to the current standard 
treatments. The discovery of new compounds and targets against both drug- and 
multidrug-resistant TB strains of MTB is therefore crucial. However, the lack of 
high-throughput animal models that adequately represent the different phases of 
human disease has severely hampered progress in this eld (1, 2). To overcome 
this obstacle, we have made an attempt by using zebrash, a host organism to 
Mycobacterium marinum, as our model system. M. marinum is very closely related 
to the human pathogen MTB, and is the causative agent of TB in sh. Importantly, 
research has shown that hallmarks of human TB, most notably the process of 
granuloma formation, are remarkably similar between sh and humans. Zebrash 
produce large clutches of eggs and their embryos develop rapidly. The initial stages 
of granuloma formation in zebrash embryos can be excellently visualized due to 
their external development and optical transparency, thus making it a valuable 
vertebrate model amenable to high-throughput research. We have recently 
developed an automatic injector that can reliably infect up to 2,000 early-stage 
embryos per hour. Having validated our system using M. marinum, we subsequently 
demonstrated that our automated approach allows high-throughput infection 
of zebrash with MTB. In addition, we have proven that the human pathogen 
survives and spreads through immune cells in this surrogate host (3). Moreover, 
the established MTB infection could be treated and cured with rst-line anti-TB 
drugs, indicating the translational power of this model. Thus, we have successfully 
developed an automated high-throughput system capable of infecting zebrash 
embryos with M. marinum and MTB thus making it suited for testing novel anti-TB 
compounds in vivo.
The alarming rate of the emergence of new drug resistant (MDR/XDR) strains of 
MTB isolated from patients, in particular HIV-infected individuals, is reason for 
global concern. This, in turn, has spurred development of new, effective vaccines, 
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as well as discovery of novel antibiotics targeting either the pathogen or the host 
(2, 4, 5). While in vitro models have shed light on processes that are central to the 
uptake and survival of the bacteria within the macrophages, they cannot represent 
the exact phenotype of MTB infection observed in vivo. MTB can persist for many 
years in specialized structures of infected and non-infected immune cells known 
as granulomas, which are extremely difcult to recapitulate in an in vitro model 
(6). Due to the persistence of MTB in granulomas and its capability to subvert the 
effects of treatment by developing drug tolerance, long-term multidrug therapy is 
required  in TB treatment to overcome tolerance. The complex interactions between 
MTB or other pathogens with their hosts could explain the discrepancies on drug 
efcacy observed between in vitro and in vivo. Therefore, in vivo animal models are 
essential for novel drug development to combat bacterial infections in humans. The 
use of non-human primate models that exhibit similar hallmarks of the human TB 
infection has been conducted in previous studies (1, 7). Using the murine model 
of TB, which offers extensive arrays of immunological reagents and genetic tools 
has strongly contributed to the understanding of the disease process in humans 
with TB infection. On the other hand, the mouse model of TB has shown to form 
loosely structured granulomas without a caseating necrosis center  that do not 
resemble the well-structured and centrally necrotizing granulomas in humans 
(2, 8). The guinea pig model has the advantage of displaying a well-structured 
granuloma formation and has therefore been used to validate anti-TB vaccines and 
drugs (9). Like guinea pigs, rabbits also display a disease spectrum that resembles 
many of the specic stages of human disease, including the formation of caseating 
granulomas (1, 8, 10). Recently, a new model of TB was developed in mini-pigs 
that could provide a better understanding in TB infection control (11). Following a 
transthoracic infection involving a low dose of MTB, the encapsulated granuloma 
structures in the lungs of the mini-pigs were found to be similar to TB granulomas 
in humans. The model was further tested in isoniazid chemotherapy combined with 
MTB fragment-based immunotherapeutic vaccination. While guinea pigs, rabbits or 
mini-pigs offer useful alternatives to murine models, these models are very costly 
and cannot be used in a high-throughput setting.
Use of zebrash as an alternative vertebrate animal model for TB research has 
gained much attention in recent years based on its many promising characteristics 
that enable a rapid high-throughput drug screening for immune-related diseases, 
including inammatory and infectious diseases and cancer (12). This is due to the 
excellent possibilities for in vivo imaging in combination with advanced tools for 
genomic and large scale mutant analysis. The context of the embryo’s developing 
immune system makes it possible to study the contribution of different immune cell 
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types to disease progression. Furthermore, due to the clear temporal separation 
of innate immunity from adaptive responses, zebrash embryos and larvae are 
particularly useful for dissecting the innate host factors involved in pathology (13). 
Recent studies have underscored the remarkable similarity of the zebrash and 
human immune systems, which is important for biomedical applications. Zebrash 
are also amenable to forward genetic screening, or reverse genetics techniques 
such as injection of morpholinos (synthetic oligonucleotides inhibitory of mRNA 
translation or pre-mRNA splicing) (14, 15). 
As an ectotherm, zebrash is one of the natural hosts of M. marinum, a close relative 
of the MTBC (16) which can cause localized granulomatous skin infection in the distal 
parts of the extremities in humans (17). Of crucial relevance, as shown by the pioneering 
work of the Ramakrishnan group, M. marinum infection of zebrash closely mimics 
the mammalian TB pattern of infection with a rapid increase in bacterial numbers 
during the initial stage of infection, and the formation of caseous granulomas which 
present characteristics typical of their human counterparts (18–21). 
The indirect study of human TB via the infection of the zebrash embryo with M. 
marinum has already led to the clarication of many important processes in the life 
cycle of the infection, in particular those underlying the mechanisms of granuloma 
formation (20–25). Infection of zebrash embryos demonstrated that granuloma 
formation is initiated in the sole context of innate immunity, prior to the development 
of T-cells (21). At later stages of zebrash development where the adaptive 
immune system starts to develop (i.e. approximately 3 week post fertilization), 
the resulting granulomas are highly similar to the granulomas found in human 
tissues (26). The importance of studying mycobacterial infections at the whole 
organism level was highlighted in the report that induction of mmp9 expression, 
enhancing macrophage recruitment to granulomas, was localized to epithelial cells 
near infected macrophages (24). Another example of the use of zebrash larvae 
to uncover a host-pathogen interaction relevant to human mycobacterial infection 
is the recent forward genetic screen by Tobin and Ramakrishnan, who mapped 
a hypersusceptibility mutation to the leukotriene biosynthesis gene, lta4h, and 
showed that heterozygosity at the LTA4H locus correlated with susceptibility of 
human populations to both TB and leprosy (27). M. marinum-infected zebrash 
larvae were recently deployed for in vivo characterization of anti-TB drug activity 
and drug-tolerance (28). Results of this study demonstrated that multidrug-
tolerant bacteria arise within days of infection, are enriched among the replicating 
intracellular population, and are amplied and disseminated by the tuberculous 
granuloma. Drug tolerance was reduced by application of bacterial efux pump 
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inhibitors such as verapamil. The zebrash embryo model has also proven to be 
useful to screen an M. marinum transposon mutant library for novel virulence 
mutants affected in granuloma formation (29). It is therefore clear that the zebrash 
mycobacterial infection model is an attractive and advantageous alternative for 
analyzing granuloma formation, disease progression, and infection control in vivo. 
The common route of infecting zebrash embryos with M. marinum is the injection 
of the pathogen into the caudal vein of the 1 day old embryo (21). This method is 
labour-intensive and generally considered to be a low-throughput technique, leading 
to major bottlenecks in drug discovery particularly in times of high-throughput 
technology and large chemical library availability. Since infection by immersion 
is not an effective alternative, we sought to establish a reliable high-throughput 
automatic injection system, which could drastically reduce labor intensity while at 
the same time also vastly increase the number of reproducibly infected embryos 
(3). Large quantities of similarly-injected/infected embryos would then allow the 
testing of sizeable compound libraries for anti-bacterial activity targeting either 
the pathogen or the host itself (5). To develop such an automated injection system, 
we rst demonstrated that the injection of 20–40 M. marinum colony-forming 
units (CFUs) into the yolk sac of embryos at early developmental stages (from 
the single cell up to the 1,024-cell stage) mimics the infection obtained with the 
well-established caudal vein injection method (Figure 4.2.1). Subsequently, we 
developed a robotised system around the yolk injection concept (Figure 4.2.2). 
The injector robot produced identical results to manual yolk injections. During 
injections, eggs are held in an agarose grid, which allows highly reproducible 
alignment, such that the yolk injections do not require camera control.  With this 
set-up 2000 injections were achieved per hour with a success rate of over 99%. 
The use of polyvinylpyrrolidone as a polymer-based carrier for the uorescently-
labelled bacteria improved concentration homogeneity and visibility of the injected 
inoculum. The injector can be coupled to a ow cytometer capable of uorescence-
based sorting of live multicellular organisms (Complex Object Parametric Analyzer 
and Sorter, COPAS). The rst application of the COPAS system is within hours after 
injection and serves to sort injected eggs into multi-well plates, simultaneously 
discarding unfertilized or uninjected eggs (Figure 4.2.3A). The second application 
of the COPAS system is the analysis of infection in the developing larvae at 4 to 
5 days post injection. The COPAS readout provides the total level of uorescence, 
representative of bacterial load, and a distribution prole of uorescence over the 
larval body, which allows convenient assessment of granuloma spreading (Figure 
4.2.3B). Demonstrating the applicability to drug screens, COPAS analysis was shown 
to discriminate correctly between untreated larvae and larvae treated with rst-line 
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anti-TB drugs (rifampicin and isoniazid). Thus, the automatic injector, coupled with 
COPAS sorting, provides a powerful high-throughput pipeline for infecting and 
analyzing zebrash embryos and offers a new in vivo tool for rapidly testing the 
efcacy of large panels of molecules on the propagation of the pathogen studied. 
Practical advantages of using M. marinum for high-throughput drug screening are 
that it can be used at lower biosafety level (BSL-2) than MTB (BSL-3) and has a 
faster growth rate. Nevertheless it was important to show that the zebrash embryo 
model can also be used to study proliferation and tissue spreading of the human 
pathogen, MTB. The use of the injector robot has been instrumental to overcome 
technical difculties of injecting a BSL-3 pathogen. Its application enabled a high 
biosafety-level study of MTB infection of zebrash embryos, showing that this 
pathogen can persist in macrophages during zebrash larval development and was 
sensitive to combinatorial rifampicin and isoniazid treatment in this model similar 
to M. marinum (3). Interestingly, we have recently demonstrated the applicability 
of this robotic injection system for the study of other bacterial infections, such 
as streptococcal species that are often associated with problems with prosthetic 
implants (unpublished results). We expect that we can also investigate the role 
of antibacterial factors in such screenings, for instance the effect of co-injected 
antibodies. Furthermore, genetic tools to investigate the host immune system, such 
as antisense morpholinos, can be easily integrated into our set-up. This shows its 
general relevance in the high-throughput study of diseases that benet from the 
use of whole vertebrate organisms.
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Figure 4.2.1 Zebrash larva at 5 days after injection of mCherry-labeled 
Mycobacterium marinum bacteria into the yolk. Spreading of bacteria into 
granuloma-like aggregates can be observed in the head and tail area
Figure 4.2.2 Schematic presentation of high-throughput injection of zebrash 
embryos with mycobacteria. Further details and movies are given in Carvalho et al. (3)
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Figure 4.2.3 High-throughput screening of mycobacterium infection using the 
COPAS system. (A) Sorting of infected embryos immediately after yolk injection. (B) 
Fluorescence proling of mycobacterial spreading into granuloma-like aggregates 
in larvae at 5 days post injection (ow cell scheme courtesy of Union Biometrica)
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CONCLUSIONS 
Carvalho et al. (3) showed for the rst time that MTB can be used to infect zebrash 
embryos, and replicate a hallmark feature of TB in this in vivo model, namely 
persistent infection of macrophages which are parasitized by the bacterium. The 
zebrash had already been shown to be an excellent vertebrate model for the study 
of granuloma formation and progression when infected with the sh pathogen 
M. marinum (24, 27). The possibility of direct infection of zebrash with MTB 
was originally viewed with scepticism, partly due to the absence of lungs in this 
organism; it is, however, important to keep in mind that human TB infection is a 
systemic disease of the entire body, and this disease can manifest itself in many 
extrapulmonary sites. We presented proof that the zebrash is a host for MTB, and 
that infection of zebrash embryos with this human pathogen leads to symptoms 
similar to those seen in M. marinum infections. We can infect zebrash embryos 
using a novel robotic screening system that operates at an unprecedented high-
throughput level, and demonstrated that it can be used to screen for TB disease 
progression in an entire living vertebrate. This animal model presents a signicant 
new tool in the study of many types of disease for which no other good cellular 
models are available. We further show that the result of rst-line drug treatment 
of TB in zebrash reliably mimics the treatment of human patients. Future research 
will need to investigate later stages of disease progression. This will make it possible 
to investigate the role of the adaptive immune system in response to MTB infection 
in zebrash. If, as expected by earlier studies with M. marinum infection, this also 
leads to the development of caseous granulomas in adult tissue and we can expect 
that zebrash will also contribute to screening for T-cell and antibody responses. 
It is therefore not improbable that high throughput screening approaches in the 
zebrash will facilitate vaccine development.  This approach may also facilitate 
the screening of M. marinum (and MTB) mutants that might impact on developing 
novel live vaccine strains. 
It should be noted that the availability of many additional sh models will also be 
important for future research. For example, the common carp is a closely related 
sh species with large body weight compared to zebrash and can produce 
hundred thousands of genetically homogeneous embryos. As carp embryos can 
also be infected with M. marinum, this model has great potential to facilitate drug 
screening and further increase the throughput level.
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